Patents by Inventor Hermann Faubl

Hermann Faubl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6942695
    Abstract: Intraocular lenses and methods producing the same are provided. The intraocular lens includes an optic and a haptic that are integrally formed together. The haptic has a polyimide coating. The polyimide coating promotes fibrosis in the surrounding eye tissue to enhance the anchoring of the IOL after it is implanted in an eye.
    Type: Grant
    Filed: April 5, 1999
    Date of Patent: September 13, 2005
    Assignee: Wessley-Jessen Corporation
    Inventors: L. Lawrence Chapoy, Hermann Faubl
  • Publication number: 20010025198
    Abstract: A contact lens with enhanced UV blocking to meet ANSI Class 1 specifications includes enhanced effective amounts of two different UV absorbing compounds. One UV absorber is a benzotriazole derivative, and the other UV absorber is a benzophenone derivative.
    Type: Application
    Filed: April 20, 2001
    Publication date: September 27, 2001
    Applicant: Wesley-Jessen Corporation
    Inventor: Hermann Faubl
  • Patent number: 6244707
    Abstract: Contact lenses, intraocular lenses and transparent plastic with enhanced UV blocking to meet ANSI Class 1 specifications include enhanced effective amounts of two different UV absorbing compounds. One UV absorber is a benzotriazole derivative, and the other UV absorber is a benzophenone derivative. The lenses are made from a polymer that incorporates both of these UV absorbers.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: June 12, 2001
    Assignee: Wesley Jessen Corporation
    Inventor: Hermann Faubl
  • Patent number: 4640910
    Abstract: Novel O-alkylsilyl derivatives of macrolide antibiotics are disclosed. These compounds have markedly superior taste properties when compared to the corresponding parent compounds.
    Type: Grant
    Filed: November 12, 1985
    Date of Patent: February 3, 1987
    Assignee: Abbott Laboratories
    Inventors: Hermann Faubl, Robert G. Stein
  • Patent number: 4491583
    Abstract: A process for inducing the production of endogenous interferon in a vertebrate animal which comprises parenterally, intranasally or topically adminstering to the animal an interferon-inducing effective amount of composition containing as the essential active ingredient a compound of the formula ##STR1## or a non-toxic acid addition salt thereof wherein R.sub.7 and R.sub.8 are each alkyl of from 12 to 30 carbon atoms and Z is selected from the group consisting of N-(lower alkyl)-piperazino and N-(W-hydroxy-lower alkyl)-piperazino, said lower alkyl groups having from 1 to 4 carbon atoms.
    Type: Grant
    Filed: July 18, 1983
    Date of Patent: January 1, 1985
    Assignee: Pfizer Inc.
    Inventors: Timothy H. Cronin, Hermann Faubl, William W. Hoffman, James J. Korst
  • Patent number: 4258061
    Abstract: Combating viral infections in vertebrate animals by administering to the animals a monoamine, a diamine or a triamine.
    Type: Grant
    Filed: February 13, 1978
    Date of Patent: March 24, 1981
    Assignee: Pfizer Inc.
    Inventors: Timothy H. Cronin, Hermann Faubl, William W. Hoffman, James J. Korst
  • Patent number: 4126639
    Abstract: The 11a-dehalogenation of 11a-halo-6-methylenetetracyclines by treating them with a secondary or a tertiary phosphine or a tertiary phosphite.
    Type: Grant
    Filed: November 19, 1976
    Date of Patent: November 21, 1978
    Assignee: Pfizer Inc.
    Inventor: Hermann Faubl
  • Patent number: 4087552
    Abstract: Combating viral infections in vertebrate animals by administering to the animals an amine selected from those having the formulae: ##STR1## and the non-toxic acid addition salts thereof wherein R.sub.1 is selected from the group consisting of alkyl of from 1 to 20 carbon atoms, aralkyl, aryloxyalkyl, hydroxyalkyl of from 2 to 8 carbon atoms and ##STR2## R.sub.2 is selected from the group consisting of alkyl of from 12 to 20 carbon atoms, aralkyl and aryloxyalkyl of from 12 to 24 carbon atoms and ##STR3## R.sup.o is alkoxy of from 1 to 18 carbon atoms; EACH OF R' and R" is selected from the group consisting of hydrogen, alkyl, alkoxy of from 1 to 18 carbon atoms; R' and R" when taken together are methylenedioxy;Provided that the total number of carbon atoms in R.sup.o, R' and R" is from 5 to 48;R.sub.3 is selected from the group consisting of hydrogen, alkyl of from 1 to 20 carbon atoms, hydroxyalkyl of from 2 to 8 carbon atoms, phenylcarbamoyloxy(lower alkyl), .omega.
    Type: Grant
    Filed: May 18, 1976
    Date of Patent: May 2, 1978
    Assignee: Pfizer Inc.
    Inventors: Timothy H. Cronin, Hermann Faubl, William W. Hoffman, James J. Korst
  • Patent number: 4034040
    Abstract: Compounds of the formula ##STR1## or a non-toxic acid addition salt thereof wherein R.sub.1 is alkyl of from 1 to 20 carbon atoms;R.sub.2 is alkyl of from 12 to 20 carbon atoms;R.sub.3 is selected from the group consisting of hydrogen and hydroxyalkyl of from 2 to 8 carbon atoms; andR.sub.4 is selected from the group consisting of hydrogen, alkyl of from 1 to 8 carbon atoms and hydroxyalkyl of from 2 to 8 carbon atoms, said compounds are useful for combating viral infections in vertebrate animals.
    Type: Grant
    Filed: March 14, 1975
    Date of Patent: July 5, 1977
    Assignee: Pfizer Inc.
    Inventors: Timothy H. Cronin, Hermann Faubl, William W. Hoffman, James J. Korst
  • Patent number: 4001321
    Abstract: Hydrogenation of a mixture prepared from a 6-deoxy-6-demethyl-6-methylenetetracycline compound, and a catalytic amount of a dicarboxylato(triphenylphosphine)rhodium(II) or dicarboxylato(substituted triphenylphosphine)rhodium(II) compound, in a reaction-inert solvent, produces the corresponding 6-deoxytetracycline compound. The hydrogenation takes place with a stereoselectivity which favors the 6.alpha.-isomer over the 6.beta.-isomer. The products are known antibacterial agents.
    Type: Grant
    Filed: October 22, 1975
    Date of Patent: January 4, 1977
    Assignee: Pfizer Inc.
    Inventor: Hermann Faubl
  • Patent number: 3980648
    Abstract: A process for the preparation of methyl 3-(2-quinoxalinylmethylene)carbazate N.sup.1,N.sup.4 -dioxide which comprises contacting a 2-quinoxalinecarboxaldehyde N.sup.1,N.sup.4 -dioxide nitrone with at least about an equimolar proportion of methyl carbazate in acidic solvent medium until reaction is substantially complete.
    Type: Grant
    Filed: March 12, 1975
    Date of Patent: September 14, 1976
    Assignee: Pfizer Inc.
    Inventors: Hermann Faubl, Banavara Lakshmana Mylari
  • Patent number: 3962131
    Abstract: Catalyst produced by the process of reacting 1 mol of rhodium trichloride and 2 mols of sodium acetate in methanol at a temperature from about 50.degree.C. to the reflux temperature of said reaction mixture, then reacting resulting reaction mixture with 2 mols of triphenylphosphine at a temperature of from about 50.degree.C. to the reflux temperature of said reaction mixture and recovering resulting insoluble material and use thereof in hydrogenating 6-deoxy-6-demethy-6-methylene-5-oxytetracycline to obtain .alpha.-6-deoxy-5-oxytetracycline.
    Type: Grant
    Filed: January 28, 1975
    Date of Patent: June 8, 1976
    Assignee: Pfizer Inc.
    Inventors: Hermann Faubl, Annette M. Belton
  • Patent number: 3950390
    Abstract: A new process for the production of citric acid, and intermediates therefor of the formula: ##SPC1##Wherein R' is cyano or CO-R.sup.2, wherein R.sup.2 is lower alkoxy, amino or hydroxy.
    Type: Grant
    Filed: August 26, 1974
    Date of Patent: April 13, 1976
    Assignee: Pfizer Inc.
    Inventor: Hermann Faubl